CYC.AU Cyclopharm Ltd
- Market cap
- AUD 53.4M
- P/E
- -
- P/B
- 1.68x
- ROE
- -110.4%
- Dividend yield
- -
- Fundamental score
- 1.4/5
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is CYC.AU undervalued?
Graham numberThe Graham number of Cyclopharm Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cyclopharm Ltd fundamental analysis
6 of 21 checks passedROE 0/2
Low return on equity (-110.4%), below 10%.
ROA 0/1
Return on assets (-70.8%) is below the industry median (-35.3%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 0/1
Last year's EPS growth (-21.9%) is below the industry median (24.9%).
Revenue Growth 2/2
Revenue grew 11.7% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (24.5%), 40% or less.
Debt Trend 1/1
Debt to equity has not risen over the past 5 years.
Cash Runway 0/2
Cash covers 0.4 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 1/1
Price to book (1.7x) is below the industry median (4.0x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Cyclopharm Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cyclopharm Ltd
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector. The company serve…
Full company profileCyclopharm Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cyclopharm Ltd annual financial statements
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 14.4M | 13.2M | 13.4M | 14.1M | 14.7M | 17.7M | 23.2M | 26.3M | 27.6M | 32.3M | 70.1M |
| Gross Profit | 7.15M | 6.35M | 5.64M | 4.87M | 2.08M | 3.20M | 5.94M | 16.1M | 17.9M | -1.46M | -95.8K |
| Operating Income | 2.02M | -1.35M | -2.54M | -5.89M | -4.17M | -6.43M | -7.28M | -5.26M | -14.3M | -18.2M | -33.6M |
| EBITDA | 1.55M | -1.35M | -1.47M | -1.38M | -7.73M | -5.79M | -6.47M | -3.84M | -13.0M | -16.4M | -30.5M |
| Net Income | 891K | -1.52M | -35.5K | -2.91M | -6.04M | -5.04M | -6.61M | -4.70M | -13.2M | -17.2M | -35.2M |
| EPS | 0.02 | -0.02 | 0.00 | -0.04 | -0.08 | -0.06 | -0.07 | -0.05 | -0.13 | -0.16 | -0.29 |
| Balance Sheet | |||||||||||
| Total Assets | 16.4M | 23.4M | 23.5M | 32.5M | 28.3M | 55.7M | 49.5M | 45.9M | 62.1M | 46.1M | 49.7M |
| Total Liabilities | 3.95M | 6.13M | 6.52M | 9.32M | 11.2M | 12.7M | 13.0M | 13.7M | 19.4M | 19.0M | 17.8M |
| Shareholders' Equity | 12.5M | 17.2M | 17.0M | 23.2M | 17.1M | 43.1M | 36.5M | 32.3M | 42.7M | 27.1M | 31.9M |
| Cash & Short-term Investments | 4.59M | 8.69M | 5.85M | 12.7M | 1.87M | 29.2M | 20.3M | 11.7M | 20.6M | 6.63M | 12.2M |
| Total Debt | - | 175K | 121K | 4.92M | 4.71M | 4.51M | 4.33M | 4.23M | 8.29M | 14.9M | 7.80M |
| Cash Flow | |||||||||||
| Operating Cash Flow | 655K | -682K | -1.11M | -489K | -8.93M | -1.63M | -5.68M | -7.20M | -12.6M | -17.3M | -30.7M |
| Capital Expenditure | 1.80M | 641K | 206K | 477K | 531K | 1.16M | 1.55M | 538K | 972K | 1.99M | 765K |
| Free Cash Flow | -1.14M | -1.32M | -1.31M | -967K | -9.47M | -2.79M | -7.23M | -7.74M | -13.5M | -19.3M | -31.5M |
| Ratios | |||||||||||
| ROE | 7.2% | -8.8% | -0.2% | -12.6% | -35.3% | -11.7% | -18.1% | -14.6% | -30.9% | -63.5% | -110.4% |
| ROA | 5.4% | -6.5% | -0.2% | -9.0% | -21.4% | -9.0% | -13.3% | -10.2% | -21.2% | -37.4% | -70.8% |
| Net Profit Margin | 6.2% | -11.6% | -0.3% | -20.7% | -41.2% | -28.5% | -28.5% | -17.8% | -47.9% | -53.3% | -50.2% |
| Debt to Equity | - | 0.01x | 0.01x | 0.21x | 0.27x | 0.10x | 0.12x | 0.13x | 0.19x | 0.55x | 0.24x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Cyclopharm Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- Sep 1, 2023
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | AUD 885K | 0.01 | - |
| 2022 | AUD 883K | 0.01 | - |
| 2021 | AUD 881K | 0.01 | - |
| 2020 | AUD 752K | 0.01 | - |
| 2019 | AUD 661K | 0.01 | - |
| 2018 | AUD 651K | 0.01 | - |
| 2017 | AUD 600K | 0.01 | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:5 on May 28, 2012.
Who owns Cyclopharm Ltd
- Insiders 48.69%
- Institutions 25.13%
- Public & others 26.18%
- Shares outstanding 126M
- Free float 64.6M
Cyclopharm Ltd company profile
- Company name
- Cyclopharm Ltd
- Ticker
- CYC.AU
- ISIN
- AU000000CYC5
- Exchange
- Australian Securities Exchange
- Listed since
- Jan 19, 2007
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 104
- Fiscal year end
- December
- Address
- 1 The Crescent, Kingsgrove, NSW, Australia, 2208
- Phone
- 61 2 9541 0411
About Cyclopharm Ltd
Cyclopharm Limited manufacture and sells medical equipment and radiopharmaceuticals in the Asia Pacific, Europe, Canada, the United States, and internationally. The company operates Technegas which offers diagnostic equipment and consumables used by physicians in the detection of pulmonary embolism and other respiratory conditions. It is also involved in the research and development; and distribution of third-party products to the diagnostic imaging sector. The company serves nuclear medicine departments. Cyclopharm Limited was founded in 1986 and is based in Kingsgrove, Australia.
Cyclopharm Ltd management
9- Mr. James S. McBrayer AIM, BSPharm, F.A.C.I.D., FAICD, GDMCEO, MD, Company Secretary & Director · born 1965
- Mr. Jason SmithChief Financial Officer
- Mr. Mathew FaragChief Operating Officer
- Ms. Sally-Ann CorneliusHead of Sales
- Ms. Niamh McAreeHead of Quality and Regulatory
- Mr. Chris QuinnHead of Service
- Ms. Sui Ling CheahFinancial Controller · born 1970
- Mr. Lynn McLauchlinGeneral Manager of Canada
- Mr. Gary T. SomervilleQuality & Regulatory Manager